LESS RISK OF RELAPSE
Relapses can cause schizophrenia symptoms to worsen over time. In the study, people taking UZEDY had a lower risk of relapse at 6 months than those who did not take UZEDY.†
UZEDY MAY HELP WITH SCHIZOPHRENIA SYMPTOMS.
A study was conducted with 542 adults living with schizophrenia. They were either given UZEDY or did not receive treatment. The study found that UZEDY may provide:
LESS RISK OF RELAPSE
Relapses can cause schizophrenia symptoms to worsen over time. In the study, people taking UZEDY had a lower risk of relapse at 6 months than those who did not take UZEDY.†
GREATER STABILITY AND IMPROVED SYMPTOMS
In the study,* 87% of people taking UZEDY once a month maintained stability with their symptoms; 61% of people taking placebo did so.
This information was found through an exploratory analysis. This means no conclusions can be made about UZEDY as a result.
FEWER SETBACKS
The relapse-free rate of people taking once-monthly UZEDY was 93% after 24 weeks (about 6 months) of treatment; 72% was the relapse-free rate of people taking a placebo.
This information was found through an exploratory analysis. This means no conclusions can be made about UZEDY as a result.
SAFETY WAS EXTENSIVELY STUDIED
SAFETY WAS EXTENSIVELY STUDIED
The most common side effects of risperidone included slow movements, stiffness, shaking, restlessness, abnormal muscle contractions or movements, drowsiness, dizziness, anxiety, blurred vision, nausea, vomiting, indigestion, diarrhea, increased saliva, constipation, dry mouth, increased appetite, weight gain, tiredness, rash, and common cold symptoms. Injection site reactions including a lump or itching were reported with UZEDY.
*In a clinical study of UZEDY, stability was defined based on patients who stayed outpatient, had few symptoms from a list of specific psychotic symptoms, and had symptom and clinical functioning scores below certain cutoffs for at least 4 weeks.
†During the maintenance stage of the RISE study (which varied in length of time), receiving UZEDY once monthly or once every 2 months significantly reduced the risk of relapse vs placebo.
92%
In a survey, 92% of people living with schizophrenia (58 out of 63) were satisfied with UZEDY.‡
Patients surveyed received UZEDY as part of a clinical trial.
‡Data were collected from 63 patients, 24 physicians, and 25 nurses in a prospective, cross-sectional companion survey assessing the perceptions regarding ease of use and satisfaction with UZEDY. The survey was administered after a minimum of 2 experiences prescribing, administering, or receiving UZEDY.
UZEDY® (risperidone) extended-release injectable suspension is a prescription medicine used in adults.
What is the most important information I should know about UZEDY?
UZEDY can cause serious side effects, including an increased risk of death in elderly people who are confused, have memory loss, and have lost touch with reality (dementia-related psychosis). UZEDY is not approved for use in patients with dementia-related psychosis.
Do not receive UZEDY if you are allergic to risperidone, paliperidone, or any of its components.
UZEDY may cause serious side effects, including:
The most common side effects of risperidone in patients with
These are not all the possible side effects of UZEDY. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.
Do not drink alcohol during treatment with UZEDY.
Before receiving UZEDY, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take or plan to take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. UZEDY and other medicines may affect each other.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For more information about UZEDY, see the full Prescribing Information, including Boxed WARNING, or talk to your healthcare provider.